chrisvoncsefalvay/vaers-outcomes huggingface dataset:
pt states that site rxn developed p/vax;rxn progressed to pain from occiput through lt trapezius, radiating down lt arm through inj site, lt forearm into dorsal surface lt hand;pt reports diff in moving arm secondary to pain;
On 4/12/13 at 4:31 pm client reported that her arm where she got her varicella vaccine was swollen with a knot at that site. Stated that she noticed it on last night, denies fever. Varicella vaccine was given on 4/10/13. States she had nurse from her job to look at it. States that she was applying ice to area. States was told that the vaccine should have been given IM and not subcutaneous.
Systemic: Hyperventilation-Mild, Systemic: Nausea-Mild, Systemic: Vomiting-Mild, Additional Details: patient has had vasovagal response before and anxiety when it comes to shots. Mother said her aunt is the same way. Patient vomited shortly after receiving her flu shot. She felt nauseous and was hyperventilating. Mother, brother, and I were trying to calm her down to take deep breaths. Patient was able to get cleaned up and left for home. She was talking and walking out. ***PATIENT DID NOT RECEIVE COVID VACCINE. It was a required field for me to fill out this form.***
Patient inadvertently given COVID vaccine at the age of 11 years. Spoke with mother three weeks after dose given when second dose was given. Mother relates no adverse events only temperature of 100.0.  Second dose not given, instructed mother to get 2nd dose after 12th birthday.
pt felt off after the vaccine, lips and face went numb, epi-pen was administered and EMS was called
This case was reported by a pharmacist via call center representative and described the occurrence of malaise in an unspecified number of adult patients who received SHINGRIX for prophylaxis. On an unknown date, the patient received SHINGRIX at an unknown dose. On an unknown date, less than a year after receiving SHINGRIX, the patient experienced malaise, flu like symptoms and fatigue. On an unknown date, the outcome of the malaise, flu like symptoms and fatigue were unknown. It was unknown if the reporter considered the malaise, flu like symptoms and fatigue to be related to SHINGRIX. Additional details were provided as follows: The age at vaccination was not reported. The health care professional stated that many of his patients complain about malaise, flu like symptoms and fatigue for several days after receiving SHINGRIX. No further information was provided.
lips swollen x 24hr DTP inj site reddened & swollen x2in diameter x 24hr;both knees sore w/redness on lt knee;
Breastfeeding; Sore arm; Muscle ache; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (Sore arm), MYALGIA (Muscle ache) and MATERNAL EXPOSURE DURING BREAST FEEDING (Breastfeeding) in a 35-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 014C21A and 025B21A) for COVID-19 vaccination.     No medical history was provided by the reporter.  Concomitant products included ESCITALOPRAM OXALATE (LEXAPRO), MAGNESIUM, VITAMIN D3 and ACETYLSALICYLIC ACID (ASPIRIN LOW) for an unknown indication.   On 03-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 01-May-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 02-May-2021, the patient experienced PAIN IN EXTREMITY (Sore arm) and MYALGIA (Muscle ache). On an unknown date, the patient experienced MATERNAL EXPOSURE DURING BREAST FEEDING (Breastfeeding). At the time of the report, PAIN IN EXTREMITY (Sore arm) and MYALGIA (Muscle ache) outcome was unknown and MATERNAL EXPOSURE DURING BREAST FEEDING (Breastfeeding) had resolved.            No treatment information was provided.   This case was linked to MOD-2021-068370 (Patient Link).
Heart palpitations in the evening and lasting 3 days on and off. No problems for the next 2 days and then palpitations, racing heart and high blood pressure. Continuing high blood pressure.
Right neck pain which was burning, searing, non-radiating; Tingling in neck, top of shoulder and right jaw and cheek; Numbness; This is a spontaneous report received from contactable reporter (Consumer). The reporter is the patient.  A 66 year-old female patient (not pregnant) received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE), administered in arm right, administration date 13Apr2021 12:45 (Lot number: EP6995) at the age of 66 years as dose 1, single for Covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: NECK PAIN (non-serious) with onset 15Apr2021, outcome "recovering", described as "Right neck pain which was burning, searing, non-radiating"; PARAESTHESIA (non-serious) with onset 15Apr2021, outcome "recovering", described as "Tingling in neck, top of shoulder and right jaw and cheek"; HYPOAESTHESIA (non-serious) with onset 15Apr2021, outcome "recovering", described as "Numbness". The events "right neck pain which was burning, searing, non-radiating", "tingling in neck, top of shoulder and right jaw and cheek" and "numbness" were evaluated at the physician office visit. Relevant laboratory tests and procedures are available in the appropriate section. Therapeutic measures were taken as a result of neck pain. Therapeutic measures were not taken as a result of paraesthesia, hypoaesthesia. Additional Information: Patient was not diagnosed with COVID-19 prior to the vaccination. Patient did not receive any other vaccines within four weeks prior to the vaccination. Patient was treated and was not responsive to extra strength of paracetamol (TYLENOL) or ibuprofen (MOTRIN) and the only relief for neck pain was to lie flat on right side with heat and not move head. The patient also experienced tingling in neck, top of shoulder, right jaw and cheek followed by numbness, which was not completely abated at time of this report. The pain was less in the morning (AM) and would escalate in mid-afternoon and evening. The pain was rated 9 out of 10. It continued for five days then started to improve. Patient had not been tested for COVID-19 since the vaccination.   No follow-up attempts are possible. No further information is expected.
pt recv vax 1993 & pt exp swelling on rt side of face & a low grade fever which was thought to be possible mumps;f/u was recv from a MD which indicated the pt was dx w/rt parotitis d/t influenza A strain H3N2 & no problem w/mumps
Ear infection; Coughing; Unevaluable event; This spontaneous case was reported by a physician and describes the occurrence of EAR INFECTION (Ear infection), COUGH (Coughing) and UNEVALUABLE EVENT (Unevaluable event) in a 37-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect product included non-company product RISANKIZUMAB (SKYRIZI [RISANKIZUMAB]) solution for injection for Psoriasis vulgaris.    Concurrent medical conditions included Drug allergy (No known drug allergy). Concomitant products included IBUPROFEN (ADVIL [IBUPROFEN]), BROMPHENIRAMINE;PSEUDOEPHEDRINE and AMOXICILLIN TRIHYDRATE (MOXICILLIN) for an unknown indication.   In March 2021, the patient started RISANKIZUMAB (SKYRIZI [RISANKIZUMAB]) (Subcutaneous) 150 mg. On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. In 2021, the patient experienced EAR INFECTION (Ear infection), COUGH (Coughing) and UNEVALUABLE EVENT (Unevaluable event). At the time of the report, EAR INFECTION (Ear infection), COUGH (Coughing) and UNEVALUABLE EVENT (Unevaluable event) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No treatment information was provided.
severely low platelets level; significant hair losss; stress; toes have been discolored; regular (2-3 times a week) migraines; mild fatigue; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 49 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in arm left, administration date 06Feb2021 10:00 (Lot number: EL9264) at the age of 49 years as dose 2, single for covid-19 immunisation. The patient had no relevant medical history. There were no concomitant medications. Vaccination history included: Bnt162b2 (Dose Number: 1, Batch/Lot No: EL9261, Location of injection: Arm Left, Vaccine Administration Time: 10:00 AM), administration date: 06Jan2021, when the patient was 49 years old, for COVID-19 Immunization. The following information was reported: FATIGUE (non-serious) with onset 2021, outcome "unknown", described as "mild fatigue"; PLATELET COUNT DECREASED (non-serious) with onset May2021, outcome "unknown", described as "severely low platelets level"; MIGRAINE (non-serious) with onset 2021, outcome "unknown", described as "regular (2-3 times a week) migraines"; ALOPECIA (non-serious) with onset 01Mar2021, outcome "not recovered", described as "significant hair losss"; STRESS (non-serious) with onset 01Mar2021, outcome "not recovered", described as "stress"; SKIN DISCOLOURATION (non-serious) with onset 01Mar2021, outcome "not recovered", described as "toes have been discolored". The events "significant hair losss", "stress" and "toes have been discolored" were evaluated at the physician office visit. Relevant laboratory tests and procedures are available in the appropriate section. Therapeutic measures were not taken as a result of alopecia, stress, skin discolouration.  Additional information: The patient had not received any other vaccines within 4 weeks prior to the COVID vaccine. The patient had not received any other medications within 2 weeks of vaccination. Patient stated patient was fine with no adverse reactions beyond mild fatigue. When patient was went for annual physical in May, patient blood results showed severely low platelets level. Patient had been having regular (2-3 times a week) migraines. In Mar, patient had started to notice significant hair losss, which initially attributed to stress. Patient was also noticed that toes have been discolored, initially thought patient had stubbed them or had a bit of an ingrown toe nail, but they have not improved. Patient looked up a picture of Covid toes and the mild case pictures are the same as patient toes. The patient did not put Al the pieces together at first. Patient have not had Covid, patient have been tested several times and have not been patient will. Patient work from home. Patient was called doctor about the symptoms and they said they dont collect adverse reaction data unless it results in hospitalization. Prior to vaccination patient was not diagnosed with COVID-19. Since the vaccination patient was tested for COVID-19. Known allergies: No.  No follow-up attempts are possible. No further information is expected.
Swelling on left side of body along the lymph nodes. Left neck (minor swelling), left underarm (armpit/pec area) severe swelling painful to the touch. Pain and arm stiffness shooting down the left arm. Pain gravitating up the left part of the head that feels like pressure leading to the crown of my head. (Vaccine info for booster reads ?Moderna 059H21A?- this is self-reported)
Woke up to use the restroom. Passed out and fell multiple (~5) times while trying to return to bed. I have never experienced that before.
Information has been received from a registered nurse concerning a patient who was vaccinated IM with RECOMBIVAX HB. Subsequently the patient had a negative hepatitis B virus (HBV) antibody titers/ had not seroconverted. The patient's outcome was not reported. Follow up information indicated that the patient did not seroconvert following vaccination. There was no patient information to provide. No additional information is expected. This is one of several reports received from the same source.
Onset 9/12 6 days after shots given on 9/7/07 with fevers, irritability, dizziness and behavioral changes of quietness, nonplayful during the day. Fever, irritability and dizziness occurred even through night from 9/12/07 ----> 9/17/07. Two visit during this time were negative for bacterial infection. Fever lasted until 9/19/07.
I ended up testing positive on Monday 04Jan2021; I ended up testing positive on Monday 04Jan2021; This is a spontaneous report from a contactable Other Health Professional (patient). A male patient of an unspecified age received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection) lot number was not reported, via an unspecified route of administration on 30Dec2020 at a single dose for COVID-19 immunization. The patient's medical history and concomitant medications were not reported. Family history included patient was "99.9% sure that his daughter at day care had direct contact (COVID-19)". It was reported that the patient received first dose on 30Dec2020, and that same Wednesday morning 99.9% sure that his daughter at day care had direct contact (COVID-19). He ended up testing positive on Monday 04Jan2021 with outcome of unknown, and was scheduled for second dose on 04Jan2021. He asked for specific recommendation for his weird situation.   Information on Lot/Batch has been requested.; Sender's Comments: Based on available information, a possible contributory role of the subject product, BNT162B2 vaccine, cannot be excluded for the reported events of suspected LOE and SARS-CoV-2 test positive due to temporal relationship.  There is limited information provided in this report.  Additional information is needed to better assess the case, including complete medical history, diagnostics, counteractive treatment measures and concomitant medications.   This case will be reassessed once additional information is available.
"COVID Arm" - red, slightly itchy rash, about 1.5" wide by 3" long, appeared on 2/26/2021 - 11 days after vaccination was administered. Not painful or swollen. Appears to be resolving.
Left arm where I got the shot has a lot of aching. Whole arm is aching. Started about 3 hours after shot.
Fever, Diarrhea, NauseaVomiting, pain and swelling at injection site Narrative:
Right sided facial droop; Bell's Palsy. Patient to office for checkup, doctor examined. No evidence of cellulitis, no tearing.
Nasal FluMist accidentally sprayed into eyes when child suddenly moved her head back. Family was contacted again 11/6/06; child is fine.
I am experiencing blurred vision; I am experiencing blurred vision, and a dark spot in my vision I also feel pressure behind my eye when moving my eye and when I'm bent down.; I also feel pressure behind my eye when moving my eye and when I'm bent down; I also feel headache in the area of my right eye; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 27 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in arm left, administration date 04Jun2021 12:30 (Lot number: EW0167) at the age of 27 years as dose 2, single for covid-19 immunisation. The patient had no relevant medical history. There were no concomitant medications. Vaccination history included: Bnt162b2 (Dose 1, single; Lot number: EW0167; Administration time: 02:00 PM; Vaccine location: Left arm), administration date: 21May2021, when the patient was 27 years old, for COVID-19 immunization. The following information was reported: VISION BLURRED (non-serious) with onset 04Jun2021 12:00, outcome "not recovered", described as "I am experiencing blurred vision"; VITREOUS FLOATERS (non-serious) with onset 04Jun2021 12:00, outcome "not recovered", described as "I am experiencing blurred vision, and a dark spot in my vision I also feel pressure behind my eye when moving my eye and when I'm bent down. "; OCULAR DISCOMFORT (non-serious) with onset 04Jun2021 12:00, outcome "not recovered", described as "I also feel pressure behind my eye when moving my eye and when I'm bent down"; SINUS HEADACHE (non-serious) with onset 04Jun2021 12:00, outcome "not recovered", described as "I also feel headache in the area of my right eye". Therapeutic measures were not taken as a result of vision blurred, vitreous floaters, ocular discomfort, sinus headache.  Additional information: The patient did not receive any other vaccines within four weeks prior to the vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. Did not experience this problem before the vaccine. No known allergies. No other medical history.  No follow-up attempts are possible. No further information is expected.
Pt stated to RN that today was her first dose of Pfizer vaccine. RN had to re-register patient for new appt, and pt was approved since she was a student. Since it was a first dose, writer didn't double-check documented vaccination history and other RN administered Pfizer vaccine. Pt then stated that 10 weeks ago she received her first dose of Moderna, but was told by home pharmacist/MD that she should re-start a new series since she waited too long after first dose. RN found prior dose manually entered in EMR, and sought IT and registration support and alerted site lead. Pt alerted of miscommunication/mistake and the agency recommendation to continue original series of Moderna instead of restart series. Pt will get second dose of Pfizer to complete this series.
Feelings of a pitched nerve in lt deltoid where flu shot was given initially; now muscle spasm & tenderness 11/29/99.Tx w/ physical therapy.
injection site redness, swelling, itch; injection site redness, swelling, itch; injection site redness, swelling, itch; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE ERYTHEMA (injection site redness, swelling, itch), VACCINATION SITE SWELLING (injection site redness, swelling, itch) and VACCINATION SITE PRURITUS (injection site redness, swelling, itch) in an 81-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 022M20A) for COVID-19 vaccination.     No Medical History Information was reported.  Concomitant products included VENLAFAXINE HYDROCHLORIDE (EFFEXOR), CLONAZEPAM (CLONAPIN) and MULTIVITAMIN [VITAMINS NOS] for an unknown indication.   On 26-Feb-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 27-Feb-2021, the patient experienced VACCINATION SITE ERYTHEMA (injection site redness, swelling, itch), VACCINATION SITE SWELLING (injection site redness, swelling, itch) and VACCINATION SITE PRURITUS (injection site redness, swelling, itch). At the time of the report, VACCINATION SITE ERYTHEMA (injection site redness, swelling, itch), VACCINATION SITE SWELLING (injection site redness, swelling, itch) and VACCINATION SITE PRURITUS (injection site redness, swelling, itch) outcome was unknown.            No treatment information was provided. This case was received via an unknown source (no reference has been entered for a health authority or license partner) on 04-Mar-2021 and was forwarded to Moderna on 05-Mar-2021.    This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE ERYTHEMA (injection site redness, swelling, itch), VACCINATION SITE SWELLING (injection site redness, swelling, itch) and VACCINATION SITE PRURITUS (injection site redness, swelling, itch) in an 81-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 022M20A) for COVID-19 vaccination.     No Medical History Information was reported.  Concomitant products included VENLAFAXINE HYDROCHLORIDE (EFFEXOR), CLONAZEPAM (CLONAPIN) and MULTIVITAMIN [VITAMINS NOS] for an unknown indication.   On 26-Feb-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 27-Feb-2021, the patient experienced VACCINATION SITE ERYTHEMA (injection site redness, swelling, itch), VACCINATION SITE SWELLING (injection site redness, swelling, itch) and VACCINATION SITE PRURITUS (injection site redness, swelling, itch). At the time of the report, VACCINATION SITE ERYTHEMA (injection site redness, swelling, itch), VACCINATION SITE SWELLING (injection site redness, swelling, itch) and VACCINATION SITE PRURITUS (injection site redness, swelling, itch) outcome was unknown.            No treatment information was provided.
Fainting twice the evening after getting the vaccine. Frequently reoccurring Paresthesia.
Patient experienced redness, hotness, itchy, SOB, tightness of chest, swollen lips, redness to face/neck.   Administered epinephrine 0.3 mg IM and diphenhydramine 50 mg IV x 1.  Monitored on sight for 45 minutes and transferred by EMS to emergency department.  In ED administered methylprednisiolone 125 mg IV x1 and pepcid 20 mg IV once.  Patient was discharged from the ED; however, developed facial pruritus, chest tightness and dyspnea and returned to ED.     Admitted to obs unit on /5 at 0845 and discharged the next day on 2/6 at 1018.
Tingling and partial numbness on the left side of my face; from my left cheekbone down to just under my chin.
9/3/05 Diarrhea 7:30 AM. 8:00 AM after eating small bowl of cereal, had nausea, vomiting. 10:30-11:00 AM, went to health center. 11:30-12:00 PM, symptoms worse and taken to hospital. Spasms occurring, finger nails blue, O2 saturation poor. Had IV's, Demerol, stool cultures done. Kept overnight. Discharge summary states gastroenteritis, Headache. msv
diff breathing, hives noted 2hr p/office visit & vax & 15min p/ingesting soy yogurt;
Pt vaccinated with Engerix B experienced localized swelling, erythema, pain ,severe